Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAP2K3 | P46734 | 2/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | MAP2K6 | P52564 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.46 |
| ▸ | NEK10 | Q6ZWH5 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 3/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42617 | 0.81 | ALDH1A1 (0.75) | MAPTALDH1A1SMN1; SMN2PIM1HSD17B10 | |
| SCHEMBL4101721 | 0.79 | ALDH1A1 (0.56) | MAPTALDH1A1SMN1; SMN2MAP2K3LCK | |
| SCHEMBL28296154 | 0.79 | ALDH1A1 (0.79) | MAPTALDH1A1SMN1; SMN2MAP2K3LCK | |
| SCHEMBL6991670 | 0.79 | ALDH1A1 (0.54) | MAPTALDH1A1SMN1; SMN2PIM1HSD17B10 | |
| SCHEMBL47270 | 0.79 | MAPT (0.54) | MAPTALDH1A1SMN1; SMN2PIM1HSD17B10 | |
| SCHEMBL3574871 | 0.78 | TDP1 (0.54) | MAPTALDH1A1SMN1; SMN2MAP2K3LCK | |
| Bicarbonate SCHEMBL11185192 | 0.75 | ALDH1A1 (0.58) | MAPTALDH1A1SMN1; SMN2PIM1HSD17B10 | |
| SCHEMBL23308057 | 0.75 | ALDH1A1 (0.48) | MAPTALDH1A1SMN1; SMN2PIM1HSD17B10 | |
| SCHEMBL4099973 | 0.75 | ALDH1A1 (0.48) | MAPTALDH1A1SMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL9114558 | 0.75 | MAPT (0.48) | MAPTALDH1A1SMN1; SMN2MAP2K3LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260056191-A1 | POLYMERS AND CONJUGATES COMPRISING THE SAME | VENTANA MEDICAL SYSTEMS, INC. (US) | 2026-02-26 | — | — | US | claimed |
| US-20250271441-A1 | APPLICATION OF CLICK CHEMISTRY FOR SIGNAL AMPLIFICATION IN IHC AND ISH ASSAYS | VENTANA MED SYST INC (US) | 2025-08-28 | — | — | US | claimed |
| US-20240123045-A1 | NONAUTOLOGOUS MULTI-STRESSED CANCER CELLS AND USES THEREOF FOR VACCINATING AND TREATING CANCERS | BRENUS PHARMA (FR) | 2024-04-18 | — | — | US | claimed |
| EP-4297874-A1 | NONAUTOLOGOUS MULTI-STRESSED CANCER CELLS AND USES THEREOF FOR VACCINATING AND TREATING CANCERS | BRENUS PHARMA (FR) | 2024-01-03 | — | — | EP | claimed |
| US-11780863-B2 | Quinone methide analog signal amplification | VENTANA MEDICAL SYSTEMS, INC. (US) | 2023-10-10 | — | — | US | claimed |
| WO-2022180251-A1 | NONAUTOLOGOUS MULTI-STRESSED CANCER CELLS AND USES THEREOF FOR VACCINATING AND TREATING CANCERS | BRENUS PHARMA (FR) | 2022-09-01 | — | — | WO | claimed |
| US-11079372-B2 | Polymers and conjugates comprising the same | VENTANA MEDICAL SYSTEMS, INC. (US) | 2021-08-03 | — | — | US | claimed |
| US-10775281-B2 | Polymer stabilization of chromogen solutions | VENTANA MEDICAL SYSTEMS, INC. (US) | 2020-09-15 | — | — | US | claimed |
| US-20200271662-A1 | PROXIMITY ASSAYS USING CHEMICAL LIGATION AND HAPTEN TRANSFER | VENTANA MED SYST INC (US) | 2020-08-27 | — | — | US | claimed |
| US-20180120306-A1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | VENTANA MED SYST INC (US) | 2018-05-03 | — | — | US | claimed |
| US-20120301886-A1 | POLYTAG PROBES | VENTANA MEDICAL SYSTEMS, INC. | 2012-11-29 | — | — | US | claimed |
| US-20120237930-A1 | METHOD OF ANALYZING CHROMOSOMAL TRANSLOCATIONS AND A SYSTEM THEREFORE | VENTANA MEDICAL SYSTEMS, INC. | 2012-09-20 | — | — | US | claimed |
| WO-2012123387-A1 | A METHOD OF ANALYZING CHROMOSOMAL TRANSLOCATIONS AND A SYSTEM THEREFORE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | claimed |
| EP-2444806-A2 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | Ventana Medical Systems, Inc. (US) | 2012-04-25 | — | — | EP | claimed |
| US-20100297725-A1 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. | 2010-11-25 | — | — | US | claimed |
| US-20100184087-A1 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. | 2010-07-22 | — | — | US | claimed |
| EP-2078197-A2 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | Ventana Medical Systems, Inc. (US) | 2009-07-15 | — | — | EP | claimed |
| US-20080268462-A1 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | VENTANA MEDICAL SYSTEMS, INC. | 2008-10-30 | — | — | US | claimed |
| WO-2008063378-A9 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | VENTANA MED SYST INC (US) | 2008-07-31 | — | — | WO | claimed |
| WO-2008063378-A2 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | VENTANA MEDICAL SYSTEMS, INC. (US) | 2008-05-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080268462-A1 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | HRH4, CRBN, NCDN | MAPT 3454/4885ALDH1A1 2096/4885SMN1; SMN2 4773/4885 |
| US-20180120306-A1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | CRBN, AHR, RORB | MAPT 2927/4885ALDH1A1 2734/4885SMN1; SMN2 4647/4885 |
| US-20260056191-A1 | POLYMERS AND CONJUGATES COMPRISING THE SAME | POLD1, POLL, INCENP | MAPT 2231/4885ALDH1A1 640/4885SMN1; SMN2 1392/4885 |
| US-20250271441-A1 | APPLICATION OF CLICK CHEMISTRY FOR SIGNAL AMPLIFICATION IN IHC AND ISH ASSAYS | MKI67, TIE1, ALK | MAPT 4162/4885ALDH1A1 37/4885SMN1; SMN2 4575/4885 |
| US-11780863-B2 | Quinone methide analog signal amplification | NQO2, SQOR, MRM1 | MAPT 4787/4885ALDH1A1 208/4885SMN1; SMN2 3661/4885 |
| US-20100297725-A1 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | CRBN, GABBR1, SHBG | MAPT 2915/4885ALDH1A1 3347/4885SMN1; SMN2 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.